Increased AGE-RAGE axis stress in methamphetamine (MA) abuse and MA-induced psychosis: associations with oxidative stress and increased atherogenicity
暂无分享,去创建一个
[1] K. Uemura,et al. Aggregation-prone A53T mutant of α-synuclein exaggerates methamphetamine neurotoxicity in SH-SY5Y cells: Protective role of cellular cholesterol , 2022, Toxicology reports.
[2] M. Maes,et al. Increased Lipid Peroxidation and Lowered Antioxidant Defenses Predict Methamphetamine Induced Psychosis , 2022, medRxiv.
[3] D. Barbosa,et al. Increased lipid peroxidation and lowered lipid-associated antioxidant defenses mediate the effects of the paraoxonase 1 (PON1) Q192R polymorphism on disabilities and final stroke core volume in mild and moderate stroke. , 2022, medRxiv.
[4] R. Holms. Long COVID (PASC) Is Maintained by a Self-Sustaining Pro-Inflammatory TLR4/RAGE-Loop of S100A8/A9 > TLR4/RAGE Signalling, Inducing Chronic Expression of IL-1b, IL-6 and TNFa: Anti-Inflammatory Ezrin Peptides as Potential Therapy , 2022, Immuno.
[5] M. Maes,et al. In Schizophrenia, the Effects of the IL-6/IL-23/Th17 Axis on Health-Related Quality of Life and Disabilities Are Partly Mediated by Generalized Cognitive Decline and the Symptomatome , 2022, medRxiv.
[6] M. Maes,et al. The interleukin-6/interleukin-23/T helper 17-axis as a driver of neuro-immune toxicity in the major neurocognitive psychosis or deficit schizophrenia: A precision nomothetic psychiatry analysis , 2022, medRxiv.
[7] M. Passarelli,et al. Advanced Glycation End Products: A Sweet Flavor That Embitters Cardiovascular Disease , 2022, International journal of molecular sciences.
[8] M. Coughlan,et al. The Role of AGE-RAGE Signalling as a Modulator of Gut Permeability in Diabetes , 2022, International journal of molecular sciences.
[9] W. Compton,et al. Methamphetamine use in the United States: epidemiological update and implications for prevention, treatment, and harm reduction , 2021, Annals of the New York Academy of Sciences.
[10] K. Kasai,et al. Fingertip advanced glycation end products and psychotic symptoms among adolescents , 2021, npj Schizophrenia.
[11] J. Cadet,et al. Neurotoxicity of methamphetamine: Main effects and mechanisms , 2021, Experimental Neurology.
[12] Michael Maes,et al. A pathway phenotype linking metabolic, immune, oxidative, and opioid pathways with comorbid depression, atherosclerosis, and unstable angina , 2021, CNS Spectrums.
[13] M. Maes,et al. In (deficit) schizophrenia, a general cognitive decline partly mediates the effects of neuro-immune and neuro-oxidative toxicity on the symptomatome and quality of life , 2021, CNS Spectrums.
[14] S. Vettoretti,et al. Sarcopenia in Chronic Kidney Disease: Focus on Advanced Glycation End Products as Mediators and Markers of Oxidative Stress , 2021, Biomedicines.
[15] J. Erusalimsky. The use of the soluble receptor for advanced glycation-end products (sRAGE) as a potential biomarker of disease risk and adverse outcomes , 2021, Redox biology.
[16] K. Prasad. AGE–RAGE Stress and Coronary Artery Disease , 2021, International Journal of Angiology.
[17] S. Sirivichayakul,et al. Inflammatory and Oxidative Pathways Are New Drug Targets in Multiple Episode Schizophrenia and Leaky Gut, Klebsiella pneumoniae, and C1q Immune Complexes Are Additional Drug Targets in First Episode Schizophrenia , 2020, Molecular Neurobiology.
[18] Mushtaq T. Abood,et al. Elevated of Calcium and Sodium Levels as a Result of Methamphetamine Addiction, Causesand Consequence , 2020 .
[19] E. Melin,et al. Higher levels of the soluble receptor for advanced glycation end products and lower levels of the extracellular newly identified receptor for advanced glycation end products were associated with lipid-lowering drugs in patients with type 1 diabetes: a comparative cross-sectional study , 2020, Lipids in health and disease.
[20] A. Suzuki,et al. Advanced glycation end products in musculoskeletal system and disorders. , 2020, Methods.
[21] Byoungduck Park,et al. Methamphetamine-Induced Neuronal Damage: Neurotoxicity and Neuroinflammation , 2020, Biomolecules & therapeutics.
[22] H. Tan,et al. Accumulation rate of advanced glycation end products in recent onset psychosis: A longitudinal study , 2020, Psychiatry Research.
[23] M. Maes,et al. Increased Levels of Plasma Tumor Necrosis Factor-α Mediate Schizophrenia Symptom Dimensions and Neurocognitive Impairments and Are Inversely Associated with Natural IgM Directed to Malondialdehyde and Paraoxonase 1 Activity , 2020, Molecular Neurobiology.
[24] J. Mayo,et al. Redox Signaling and Advanced Glycation Endproducts (AGEs) in Diet-Related Diseases , 2020, Antioxidants.
[25] E. London,et al. Methamphetamine-associated psychosis: links to drug use characteristics and similarity to primary psychosis , 2020, International journal of psychiatry in clinical practice.
[26] Yasuhiko Yamamoto,et al. CD38, CD157, and RAGE as Molecular Determinants for Social Behavior , 2019, Cells.
[27] S. Faraone,et al. Prevalence and Consequences of the Nonmedical Use of Amphetamine Among Persons Calling Poison Control Centers , 2019, Journal of attention disorders.
[28] M. Pellegrini,et al. ZEB1 insufficiency causes corneal endothelial cell state transition and altered cellular processing , 2019, bioRxiv.
[29] Yasuhiko Yamamoto,et al. JNK and ATF4 as two important platforms for tumor necrosis factor‐α–stimulated shedding of receptor for advanced glycation end products , 2018, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[30] F. Biagioni,et al. Epigenetic Effects Induced by Methamphetamine and Methamphetamine-Dependent Oxidative Stress , 2018, Oxidative medicine and cellular longevity.
[31] Min Zhao,et al. A Comparison Study of Working Memory Deficits between Patients with Methamphetamine-Associated Psychosis and Patients with Schizophrenia , 2018, General Psychiatry.
[32] M. Nechifor. Magnesium in addiction - a general view. , 2018, Magnesium research.
[33] M. Lippman,et al. Targeting RAGE Signaling in Inflammatory Disease. , 2018, Annual review of medicine.
[34] R. Mcketin,et al. A systematic review of risk factors for methamphetamine-associated psychosis , 2018, The Australian and New Zealand journal of psychiatry.
[35] A. Keshavarzian,et al. Colon dysregulation in methamphetamine self-administering HIV-1 transgenic rats , 2018, PloS one.
[36] E. Bulska,et al. Effect of Disturbances of Zinc and Copper on the Physical and Mental Health Status of Patients with Alcohol Dependence , 2018, Biological Trace Element Research.
[37] G. Salekdeh,et al. Advanced glycation end‐products produced systemically and by macrophages: A common contributor to inflammation and degenerative diseases , 2017, Pharmacology & therapeutics.
[38] A. Moszczynska,et al. Molecular, Behavioral, and Physiological Consequences of Methamphetamine Neurotoxicity: Implications for Treatment , 2017, The Journal of Pharmacology and Experimental Therapeutics.
[39] P. Zhu,et al. Impact of chronic methamphetamine treatment on the atherosclerosis formation in ApoE-/- mice fed a high cholesterol diet. , 2017, Oncotarget.
[40] V. Apostolopoulos,et al. Methamphetamine: Effects on the brain, gut and immune system , 2017, Pharmacological research.
[41] Meijuan Zhang,et al. The levels of triglyceride and total cholesterol in methamphetamine dependence , 2017, Medicine.
[42] Zheng Li,et al. Association of Polymorphisms of the Receptor for Advanced Glycation Endproducts Gene with Schizophrenia in a Han Chinese Population , 2017, BioMed research international.
[43] M. Memo,et al. Nutrition and AGE-ing: Focusing on Alzheimer's Disease , 2017, Oxidative medicine and cellular longevity.
[44] K. Kasai,et al. The regulation of soluble receptor for AGEs contributes to carbonyl stress in schizophrenia. , 2016, Biochemical and biophysical research communications.
[45] K. Uemura,et al. Necroptosis-like Neuronal Cell Death Caused by Cellular Cholesterol Accumulation* , 2016, The Journal of Biological Chemistry.
[46] Habibeh Khoshbouei,et al. Methamphetamine Regulation of Firing Activity of Dopamine Neurons , 2016, The Journal of Neuroscience.
[47] M. Kidd,et al. Methamphetamine-induced psychosis: Clinical features, treatment modalities and outcomes , 2016, The South African journal of psychiatry : SAJP : the journal of the Society of Psychiatrists of South Africa.
[48] Qingxin Cao,et al. Soluble receptor for advanced glycation end products mitigates vascular dysfunction in spontaneously hypertensive rats , 2016, Molecular and Cellular Biochemistry.
[49] M. Glomb,et al. Pathways of the Maillard reaction under physiological conditions , 2016, Glycoconjugate Journal.
[50] P. Zhu,et al. Chronic administration of methamphetamine promotes atherosclerosis formation in ApoE-/- knockout mice fed normal diet. , 2015, Atherosclerosis.
[51] V. Kakkar,et al. Hypercholesterolemia Induced Immune Response and Inflammation on Progression of Atherosclerosis in Apobtm2SgyLdlrtm1Her/J Mice , 2015, Lipids.
[52] M. Itokawa,et al. Advanced glycation end products and schizophrenia: A systematic review. , 2015, Journal of psychiatric research.
[53] C. Fontes-Ribeiro,et al. The TNF-α/Nf-κB Signaling Pathway has a Key Role in Methamphetamine–Induced Blood–Brain Barrier Dysfunction , 2015, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[54] H. Arai,et al. Significance of measurements of peripheral carbonyl stress markers in a cross-sectional and longitudinal study in patients with acute-stage schizophrenia. , 2014, Schizophrenia bulletin.
[55] M. Torres-Ramos,et al. Receptor for AGEs (RAGE) as mediator of NF-kB pathway activation in neuroinflammation and oxidative stress. , 2014, CNS & neurological disorders drug targets.
[56] Dan J Stein,et al. The neurobiology of methamphetamine induced psychosis , 2014, Front. Hum. Neurosci..
[57] K. Koriem,et al. Chlorogenic and Caftaric Acids in Liver Toxicity and Oxidative Stress Induced by Methamphetamine , 2014, Journal of toxicology.
[58] Stuart A. Collins,et al. Neurotoxicity of methamphetamine and 3,4-methylenedioxymethamphetamine. , 2014, Life sciences.
[59] K. Prasad. Low Levels of Serum Soluble Receptors for Advanced Glycation End Products, Biomarkers for Disease State: Myth or Reality , 2014, International Journal of Angiology.
[60] A. Simm,et al. Role of advanced glycation end products in cellular signaling , 2014, Redox biology.
[61] N. Hurst,et al. Cardiac complications of adult methamphetamine exposures. , 2013, The Journal of emergency medicine.
[62] M. Iyo,et al. Evidence for Shared Genetic Risk Between Methamphetamine-Induced Psychosis and Schizophrenia , 2013, Neuropsychopharmacology.
[63] A. Amad,et al. Increased advanced glycation end-products (AGEs) assessed by skin autofluorescence in schizophrenia. , 2013, Journal of psychiatric research.
[64] Y. Qiu,et al. Activation of receptor for advanced glycation end products contributes to aortic remodeling and endothelial dysfunction in sinoaortic denervated rats. , 2013, Atherosclerosis.
[65] G. Fritz,et al. RAGE regulation and signaling in inflammation and beyond , 2013, Journal of leukocyte biology.
[66] A. Baker,et al. Dose-related psychotic symptoms in chronic methamphetamine users: evidence from a prospective longitudinal study. , 2013, JAMA psychiatry.
[67] Chang-li Lu,et al. Gender differences in abusers of amphetamine-type stimulants and ketamine in southwestern China. , 2013, Addictive behaviors.
[68] E. Jönsson,et al. Is the Gly82Ser polymorphism in the RAGE gene relevant to schizophrenia and the personality trait psychoticism? , 2012, Journal of psychiatry & neuroscience : JPN.
[69] A. Tungtrongchitr,et al. Alterations in malondialdehyde levels and laboratory parameters among methamphetamine abusers. , 2011, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.
[70] E. Leal,et al. Methamphetamine transiently increases the blood–brain barrier permeability in the hippocampus: Role of tight junction proteins and matrix metalloproteinase-9 , 2011, Brain Research.
[71] H. Jo,et al. Animal, in vitro, and ex vivo models of flow-dependent atherosclerosis: role of oxidative stress. , 2011, Antioxidants & redox signaling.
[72] E. Walker,et al. Diagnostic and Statistical Manual of Mental Disorders , 2013 .
[73] R. Bevins,et al. Methamphetamine-Associated Psychosis , 2011, Journal of Neuroimmune Pharmacology.
[74] F. Barale,et al. Serum levels of soluble receptor for advanced glycation endproducts (sRAGE) in patients with different psychiatric disorders , 2011, Neuroscience Letters.
[75] H. Zhang,et al. HMGB1 activates nuclear factor-κB signaling by RAGE and increases the production of TNF-α in human umbilical vein endothelial cells. , 2010, Immunobiology.
[76] Melissa G. Piper,et al. sRAGE Induces Human Monocyte Survival and Differentiation , 2010, The Journal of Immunology.
[77] D. Matsuzawa,et al. Enhanced carbonyl stress in a subpopulation of schizophrenia. , 2010, Archives of general psychiatry.
[78] H. Zhang,et al. Role of High-Mobility Group Box 1 Protein in the Pathogenesis of Intestinal Barrier Injury in Rats With Severe Acute Pancreatitis , 2010, Pancreas.
[79] P. Couraud,et al. Methamphetamine Disrupts Blood–Brain Barrier Function by Induction of Oxidative Stress in Brain Endothelial Cells , 2009, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[80] B. Bogerts,et al. A New Pathophysiological Aspect of S100B in Schizophrenia: Potential Regulation of S100B by Its Scavenger Soluble RAGE , 2009, Biological Psychiatry.
[81] P. Saftig,et al. A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane‐bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10) , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[82] J. Tiihonen,et al. Pharmacotherapy of Methamphetamine Addiction: An Update , 2008, Substance abuse.
[83] G. Hanson,et al. Mechanisms of methamphetamine-induced dopaminergic neurotoxicity , 2006, The AAPS Journal.
[84] Hiroshi Yamamoto,et al. RAGE and Soluble RAGE: Potential Therapeutic Targets for Cardiovascular Diseases , 2007, Molecular medicine.
[85] M. Kamal,et al. Serum antioxidant micromineral (Cu, Zn, Fe) status of drug dependent subjects: Influence of illicit drugs and lifestyle , 2007, Substance abuse treatment, prevention, and policy.
[86] L. Ferrucci,et al. Circulating glycotoxins and dietary advanced glycation endproducts: two links to inflammatory response, oxidative stress, and aging. , 2007, The journals of gerontology. Series A, Biological sciences and medical sciences.
[87] A. Sastry,et al. Receptor for advanced glycation end products activation injures primary sensory neurons via oxidative stress. , 2007, Endocrinology.
[88] J. Meador-Woodruff,et al. Plasma copper, iron, ceruloplasmin and ferroxidase activity in schizophrenia , 2006, Schizophrenia Research.
[89] Ikuko Miyazaki,et al. Direct evidence for expression of dopamine receptors in astrocytes from basal ganglia , 2004, Brain Research.
[90] T. Hasegawa,et al. Role of Tumor Necrosis Factor-α in Methamphetamine-Induced Drug Dependence and Neurotoxicity , 2004, The Journal of Neuroscience.
[91] Yong Woo Lee,et al. Methamphetamine induces AP‐1 and NF‐κB binding and transactivation in human brain endothelial cells , 2001, Journal of neuroscience research.
[92] W. Slikker,et al. Methamphetamine‐Induced Dopaminergic Neurotoxicity: Role of Peroxynitrite and Neuroprotective Role of Antioxidants and Peroxynitrite Decomposition Catalysts , 2001, Annals of the New York Academy of Sciences.
[93] H. Meltzer,et al. Lower serum zinc in major depression is a sensitive marker of treatment resistance and of the immune/inflammatory response in that illness , 1997, Biological Psychiatry.
[94] B Powis,et al. The Severity of Dependence Scale (SDS): psychometric properties of the SDS in English and Australian samples of heroin, cocaine and amphetamine users. , 1995, Addiction.
[95] P. Vischer,et al. A possible role of catecholamines in atherogenesis and subsequent complications of atherosclerosis. , 1987, Experimental pathology.
[96] R. Levy,et al. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.